share_log

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

Benzinga ·  Mar 27, 2023 22:15

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment